Adherence assessments and the use of depot antipsychotics in patients with schizophrenia

Journal of Clinical Psychiatry

Volumn 62, Issue 7, 2001, Pages 545-551

  Valenstein, M ^a   Copeland, L A ^a   Owen, R ^a   Blow, F C ^a   Visnic, S ^a  

^a SMITREC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; AGED; ARTICLE; CAUCASIAN; DRUG MEGADOSE; DRUG USE; ETHNOLOGY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOIDISM; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOMATOLOGY;

EID: 0034893513     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v62n07a08     Document Type: Article

References (52)

1. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample: The National Comorbidity Survey
2. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment
3. Long-term depot maintenance of chronic schizophrenic out-patients: The seven year follow-up of the Medical Research Council fluphenazine/placebo trial I: Course of illness, stability of diagnosis, and the role of a special maintenance clinic
4. Depot antipsychotic drugs: Place in therapy
5. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder
6. Medication noncompliance and substance abuse among patients with schizophrenia
7. Medication compliance and health education among outpatients with chronic mental disorders
8. Depot antipsychotic drugs and prevention of psychotic relapse
9. Medication compliance in patients with chronic schizophrenia: Implications for the community management of mentally disordered offenders
10. The Scottish First Episode Schizophrenia Study, 2: Treatment: Pimozide versus flupenthixol
11. Medication noncompliance in schizophrenia: Codification and update
12. A two-year prospective study of treatment compliance in patients with schizophrenia
13. Predicting medication adherence in severe mental disorders
14. Predicting medication noncompliance after hospital discharge among patients with schizophrenia
15. Compliance in psychosis
16. From noncompliance to collaboration in the treatment of schizophrenia
17. Clinical symptomatology and drug compliance in schizophrenic patients
18. Long-term depot antipsychotics: A risk-benefit assessment
19. Depot neuroleptic therapy: An underutilized treatment option
20. Depot neuroleptic therapy: Clinical considerations
21. Fortnightly review: Treatment of schizophrenia
22. Atypical antipsychotic agents: A critical review
23. Depot neuroleptics: A comparative review of standard, intermediate, and low-dose regimens
24. Dose response of prophylactic antipsychotics
25. Practice guidelines for the treatment of patients with schizophrenia
26. At issue: Translating research into practice: The schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations
27. Antipsychotic drug: A study of the prescription pattern in a total sample of patients with a schizophrenic syndrome in one catchment area in the county of Uppland, Sweden, in 1991
28. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses
29. Dosing issues and depot medication in the maintenance treatment of schizophrenia
30. Relapse and rehospitalization during maintenance treatment of schizophrenia: The effects of dose reduction and family treatment
31. Longitudinal assessment of inpatient use and functioning of seriously mentally ill veterans with and without co-occurring substance use disorders
32. The effectiveness of specialized treatment programs for veterans with serious and persistent mental illness: 3-Year follow-up study
33. The Brief Psychiatric Rating Scale
34. The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling
35. Post hoc pairwise comparisons for the chi-square test of homogeneity of proportions
36. Utilization of depot neuroleptic medication in psychiatric inpatients
37. Demographic predictors of the use of injectable versus oral antipsychotic medications in outpatients
38. Racial disparity in psychotropic prescription patterns for persons with serious mental illness
39. Psychiatric diagnosis of African Americans: Diagnostic divergence in clinician-structured and semistructured interviewing conditions
40. Misdiagnosis of schizophrenia in bipolar patients: A multiethnic comparison
41. Patterns of usual care for schizophrenia: Initial results from the schizophrenia Patient Outcomes Research Team (PORT) Client Survey
42. Race, racism, and epidemiological surveys
43. Race, quality of care, and antipsychotic prescribing practices in psychiatric emergency services
44. The effects of race on diagnosis and disposition from a psychiatric emergency service
45. Racial differences in the diagnosis of psychosis
46. Racial and geographic differences in the psychopathology of schizophrenia
47. Fluphenazine decanoate: A clinical problem?
48. The need for depot atypical antipsychotics in the US
49. Kinetics and safety of a novel risperidone depot formulation
50. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms